CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRISPR Therapeutics AG (CRSP) is not a strong buy for a beginner investor with a long-term focus at this time. While the company has significant growth potential in the gene-editing space, its financial performance, insider selling trends, and lack of immediate positive trading signals suggest a cautious approach. The stock may be worth monitoring for future entry points when more favorable conditions arise.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 63.346, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a resistance level (R1: 54.873), suggesting limited immediate upside potential.
Positive sentiment around the Casgevy gene-editing therapy, with expectations for significant sales growth.
Promising investigational drugs like CTX611 and CTX310 with upcoming clinical trial data.
Strong cash position of $2.4 billion, providing financial stability for R&D and pipeline growth.
Insider selling has increased significantly by 476.16% over the last month, indicating potential lack of confidence from insiders.
The company reported a net loss of $122.9 million in Q1 2026, with only $1.46 million in revenue from Casgevy.
Lack of recent congress trading data or significant hedge fund activity.
CRISPR Therapeutics reported a net loss of $122.9 million in Q1 2026, with minimal revenue of $1.46 million from Casgevy. Despite the losses, the company maintains a strong cash position of $2.4 billion, which supports its ability to fund ongoing research and development.
Analyst sentiment is mixed but slightly positive. Morgan Stanley upgraded the stock to Equal Weight with a price target of $60, citing improved visibility on the Casgevy launch. Other analysts have raised price targets, with Citi maintaining a Buy rating and a target of $82. However, BofA lowered its target to $83 from $86 while maintaining a Buy rating.
